person
Martin E.
- Country
- Germany
- Department
- Abteilung für päd. Hämatologie und Onkologie
Research Overview
assignment
16
Clinical Trials ·
- A Phase I/II Study of Pembrolizumab (MK-3475) in children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
- International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
- Phase 1/2 Study on Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Patients with Hematologic Malignancies or Solid Tumors
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
191
Sites with multiple studies
Has run more than one trial at 191 of 285 partner sites.
Specializations
Pediatric Oncology
This investigator specializes in the treatment of pediatric solid tumors and hematologic malignancies, with particular focus on innovative therapeutic approaches for rare childhood cancers.
- Hepatic Tumors (Hepatoblastoma and Hepatocellular Carcinoma)
- Rhabdomyosarcoma and Fusion-Driven Sarcomas
- Medulloblastoma and Brain Tumors
- Germ Cell Tumors
Targeted Therapies
The investigator works on developing and implementing personalized treatment approaches, including targeted immunotherapies and novel drug combinations.
- Peptide Vaccines for Specific Cancer Types
- CAR-T Cell Therapy for B-Cell Malignancies
- Immunotherapy with Pembrolizumab
- Fusion-Targeted Treatments
Clinical Research Focus
The investigator conducts research in treatment optimization and novel therapeutic strategies for various pediatric cancers.
- Multi-Modal Treatment Approaches
- Risk-Adapted Therapy Protocols
- Radiotherapy Optimization
- High-Dose Chemotherapy Regimens
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.